The treatment of AML: Current status and novel approaches

Hematology

Volumn 10, Issue SUPPL. 1, 2005, Pages 50-53

  Burnett, Alan K ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CLOFARABINE; CYTARABINE; FLT3 LIGAND; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GLYCOPROTEIN P; PROTEIN FARNESYLTRANSFERASE; TIPIFARNIB;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGRAFT; AUTOGRAFT; CLINICAL TRIAL; CYTOGENETICS; DOSE RESPONSE; GRAFT VERSUS HOST REACTION; HUMAN; LIVER TOXICITY; MUTATION; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; REVIEW; STEM CELL TRANSPLANTATION; TANDEM REPEAT;

ACUTE DISEASE; AGE FACTORS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID;

EID: 29244475038     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330512331389773     Document Type: Review

References (29)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-1062.
2. Burnett AK. Acute myeloid leukemia: Treatment of adults under 60 years. Rev Clin Exp Hematol 2002;6:26-45.
3. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JKH, Harrison G. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML10 Trial. Brit J Haematol 2002;118:385-400.
4. Burnett AK, Goldstone AH, Stevens R, Hann IM, Rees JK, Gray RG, Wheatley K. Randomised comparison of addition of autologous bone-marrow transplantation in intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 Trial. Lancet 1998;351:700-708.
5. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, et al. Suciu. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. New Engl J Med 1995,332:217-223.
6. Harousseau JL, Cahn JY, Pignon B, Witz F, Milpied N, Delain M, Lioure B, Lamy T, Desablens B, Guilhot F, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 1997;90:2978-2986.
7. Cassileth PA, Harrington DP, Appelbaum F, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM, Blume KG, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. New Eng J Med 1998;339:1649-1656.
8. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison C, Wheatley K, Burnett AK, Goldstone AH. The predictive value of hierarchical cytogenetic classification in older adults with AML: analysis of 1065 patients entered into the MRC AML11 Trial. Blood 2001;98:1312-1320.
9. Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, Rees JK, Stevens RF, Walker H. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Brit J Haematol 1999;107:69-79.
10. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer S, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 Trials. Blood 2001;98:1752-1759.
11. Burnett AK, Wheatley K, Goldstone AH, Gibson K, Webb D, Prentice AG, Milligan D. MRC AML12: A comparison of ADE vs MAE and S-DAT vs H-DAT ± Retinoic Acid for induction and four vs five total courses using chemotherapy or stem cell transplant in consolidation in 3459 patients under 60 years with AML. Blood 2002;100:155a.
12. Breems DA, van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF, Vellenga E, de Greef GE, Jacky E, van der Lelie J, Boogaerts MA, Lowenberg B. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005;23:1969-1978.
13. Burnett AK, Hills R, Goldstone AH, Milligan D, Prentice A, Hann I, Webb D, Gibson B, Wheatley K. The impact of transplant in AML in 2nd CR: A prospective study of 741 in the MRC AML10 and 12 Trials. Blood 2004;104:179a.
14. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, David TA, Waddelow CL, Phan AT, Colburn DE, Rashid A, Estey AH. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001;15:406-413.
15. Kell WJ, Burnett AK, Chopra R, Yin JAL, Clark RE, Rohatiner A, Culligan D, Hunter A, Prentice AG, Milligan D. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukaemia. Blood 2003;102:4277-4283.
16. Hiddeman W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wormann B, Buchner T. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 1999;17:3569-3576.
17. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukaemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1302-1311.
18. van der Holt B, Lowenberg B, Burnett AK, Knauf KU, Shepherd J, Piccaluga PP, Ossenkoppele G, Verhoef GE, Ferrant A, Crump M, et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with peviously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 2005; (Submitted).
19. van der Holt B, Sonneveld P, Burnett AK, Vossebeld PJM, Beverloo B, Rosenkranz G, Dugan M, van Putten W, Wheatley K, Lowenberg B. Daunorubicin and Cytarabine compared with Daunorubicin, Cytarabine and the MDR1 reversal agent PSC-833 in elderly patients with acute myelogenous leukemia. Blood 2004;104:246a.
20. Kell J. Emerging treatments in acute myeloid leukaemia. Expert Opin Emerg Drugs 2004;9:55-71.
21. Giles FJ, Stopeck AT, Silverman LR, et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003;102:795-801.
22. Stone RM, Klimek V, Deangelo DJ, et al. PKC412, an oral FLT3 inhibitor, has activity in mutant FLT3 acute myeloid leukemia (AML): A phase II clinical trial. Blood 2002;101:16-11.
23. Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004;103:3669-3676.
24. Knapper S, Burnett AK, Kell WJ, Clark R, Craig J, Chopra R, Culligan D, Levis MJ, Littlewood T, Russell NH, Small D. A Phase II trial of the FLT3 inhibitor CEP701 as first line treatment for older patients with acute myeloid leukaemia not considered fit for intensive chemotherapy. Am Soc Hematol 2004; Submitted (Abstract).
25. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001;97:3361-3369.
26. Harousseau JL, Reiffers J, Lowenberg B, et al. Zarnestra™ (R115777) in patients with relapsed and refractory acute myelogenous leukemia (AML): results of a multicenter phase 2 study. Blood 2003;102:176a.
27. Lancet JE, Gotlib J, Gojo I, Feldman EJ, Morris L, Thibault A, Liesveld JL, Greer J, Dugan K, Raponi M, et al. Tipifarnib (ZARNESTRA™) in previously untreated poor risk AML of the elderly: updated results of a multicenter phase 2 trial. Blood 2004;104:249a.
28. Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Garcia-Manero G, Giles F, Faderl S, O'Brien S, Jeha S, Davis J, et al. Phase 2 clincal and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003;102:2379-2386.
29. Burnett AK, Russell N, Kell WJ, Milligan D, and Culligan D. A phase 2 evaluation of single agent Clofarabine as first line treatment for older patients with AML who are not considered fit for intensive chemotherapy. Blood 2004;104:248a (Abstract)